Newcastle University Featured PhD Programmes
University of Kent Featured PhD Programmes
National University of Ireland, Galway Featured PhD Programmes
University of St Andrews Featured PhD Programmes
University of Bristol Featured PhD Programmes
"hypertension"×
10 miles

hypertension PhD Projects, Programs & Scholarships

We have 25 hypertension PhD Projects, Programs & Scholarships

  • "hypertension" ×
  • clear all
Order by 
Showing 1 to 10 of 25
  Resistant Hypertension – pathological insights from cardiac microvascular perfusion and mechanics.
  Dr D Oxborough, Prof K George, Prof GYH Lip
Applications accepted all year round
Hypertension commonly predisposes to many cardiovascular complications, including atrial fibrillation, heart failure and stroke. Importantly the heart is responsible for blood pressure yet suffers the consequences of uncontrolled hypertension.
  Translation of Cardiovascular Control Models: Are ‘resistant hypertension’ patients truly drug resistant and does neuronal dysregulation contribute?
  Dr R Barrett-Jolley, Prof GYH Lip, Dr A Shantsila
Applications accepted all year round
Hypertension is major health problem across the world affecting 30-40% of adults, and its prevalence continues to grow, especially in developing countries.
  Regulation of SOX17 by HOXa5: a therapeutic target in pulmonary arterial hypertension
  Dr C Rhodes, Prof M Wilkins, Prof J Ferrer, Dr I Cebola
Application Deadline: 31 January 2019
Applications are invited for a BHF 4 year MRes/PhD studentship starting in October 2019 at the Imperial Centre for Translational and Experimental Medicine (ICTEM), Hammersmith Campus.
  Two pore channel segment 2: a new partner in crime for mTORC1 in pulmonary hypertension
  Prof A M Evans
Applications accepted all year round
Mechanistic target of Rapamycin (mTOR) and regulatory protein of TOR (Raptor) complexes (mTORC1) promote idiopathic- and hypoxic pulmonary hypertension (PH), facilitating pulmonary arterial smooth muscle cell (PASMC) growth, proliferation, and thus pulmonary vascular remodelling.
  MRC DiMeN Doctoral Training Partnership: Identifying inhibitors specific to the OPG-kinome: towards novel treatments for Pulmonary Arterial Hypertension (PAH)
  Dr A Lawrie, Dr R Thompson
Application Deadline: 21 January 2019
Pulmonary arterial hypertension (PAH) is a fatal progressive disease with a median life expectancy of 2.8 years, untreated.
  Study of the osmopressor response in human volunteers with and without hypertension
  Dr M Carew, Dr H Moir
Applications accepted all year round
The osmopressor response refers to the increase in blood pressure and associated change in heart rate that occurs in some people after ingestion of water (1).
  Re-purposing established drugs for the resolution of pulmonary arterial hypertension (PAH)
  Research Group: Pharmacology and Experimental Therapeutics
  Dr T Nasim, Prof T Palmer
Applications accepted all year round
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death.
  Therapeutic resolution of pulmonary arterial hypertension (PAH) by natural products
  Research Group: Pharmacology and Experimental Therapeutics
  Dr T Nasim, Prof C Wright
Applications accepted all year round
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death.
  MRC DiMeN Doctoral Training Partnership: Developing novel therapies for babies born with univentricular hearts
  Prof H Arthur, Dr A Lawrie
Application Deadline: 21 January 2019
Outstanding graduate scientists are invited to apply for a PhD Studentship to study the molecular mechanisms that cause detrimental pulmonary vascular remodelling in babies born with univentricular hearts, and to develop treatments that will prevent this problem and protect the infant lungs through childhood.
  Cardiotoxicity of cancer drugs targeting the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade
  Prof A Clerk
Applications accepted all year round
"Heart failure is a leading cause of morbidity and mortality worldwide. The contractile cells of the heart, cardiomyocytes, possess many protective mechanisms, allowing them to withstand pathophysiological stresses.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2019
All rights reserved.